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Abstract Afﬁnity reagents recognizing constant parts of
antibody molecules are invaluable tools in immunotech-
nology applications, including puriﬁcation, immobiliza-
tion, and detection of immunoglobulins. In this article,
murine IgG1, the primary isotype of monoclonal antibodies
(mAbs) was used as target for selection of novel binders
from a combinatorial ribosome display (RD) library of 10
11
afﬁbody molecules. Four rounds of selection using three
different mouse IgG1 mAbs as alternating targets resulted
in the identiﬁcation of binders with broad mIgG1 recog-
nition and dissociation constants (KD) in the low nanomolar
to low micromolar range. For one of the binders, denoted
Zmab25, competition in binding to full length mIgG1 by a
streptococcal protein G (SPG) fragment and selective
afﬁnity capture of mouse IgG1 Fab fragments after papain
cleavage of a full mAb suggest that an epitope functionally
overlapping with the SPG-binding site in the CH1 domain
of mouse IgG1 had been addressed. Interestingly, biosensor-
based binding experiments showed that neither human
IgG1 nor bovine Ig, the latter present in fetal bovine serum
(FBS) was recognized by Zmab25. This selective binding
proﬁle towards murine IgG1 was successfully exploited in
species selective recovery of two different mouse mAbs
from complex samples containing FBS, resembling a
hybridoma culture supernatant.
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Introduction
Development of different technologies for handling large
collections of genotype–phenotype pairs has provided the
ﬁeld of protein engineering with means for identiﬁcation of
particular entities with desired properties [1]. In the ﬁeld of
afﬁnity biotechnology, this has contributed to the existence
of a plethora of different classes of non-immune system-
derived binding molecules, based on protein frameworks of
different origin, size, structural organization, and bio-
physical stability [2–4]. One such class of binding proteins
is denoted as afﬁbody molecules, which are based on a
small 58 aa three-helix bundle protein framework derived
from the immunoglobulin binding receptor staphylococcal
protein A (SPA). From libraries constructed by combina-
torial protein engineering principles, afﬁbody molecules
have been isolated based on their capability of selective
binding to desired target proteins for later use in a variety
of different afﬁnity technology applications, including, for
example, bioseparation, protein microarrays, in vivo
imaging, and therapy [5–8]. The technologies used for
linking genotype and phenotype during these selections
have been phage display, cell display, and protein fragment
complementation assay (PCA), or combinations thereof, all
methods relying on the transformation of bacterial cells
with plasmid DNA as one step in the experimental proce-
dure, in practice limiting the sizes of libraries obtained
[5, 9–11].
Even if these new classes of reagents are being
increasingly used in various experimental modalities, tra-
ditional monoclonal antibodies (mAbs) are still the most
widely used reagents in numerous in vitro assay formats,
including, for example, ELISA, western blotting, immu-
noﬂuorescence, and immunohistochemistry [12]. Today,
several species of laboratory animals including rats and
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for fusion to immortal cell lines for a sustained production
of mAbs. However, the once pioneering work with murine
cells is still the dominant route to how mAbs are generated,
with mouse IgG1, IgG2a, or IgG2b as the most common
isotypes of produced reagents. Proteins capable of binding
to conserved parts of such mAbs have proven to be of
immense importance in immunobiotechnology, for exam-
ple, in puriﬁcation, detection, and capture of mAbs and
their fragments in different bioseparation and assay formats
[13, 14]. Two examples of such reagents are SPA and
streptococcal protein G (SPG), each containing several
homologous domains, which bind with various strengths to
different fragments of immunoglobulins in a highly spe-
cies, sequence and condition-dependent manner. For
example, while SPA binds with high afﬁnity to human
IgG1 Fc under physiological conditions, murine IgG1 Fc is
not or only very weakly bound under the same conditions,
requiring the use of a high salt concentration (3 M NaCl)
and/or an elevated pH to increase the afﬁnity for practical
use [15, 16]. SPG in contrast binds well to murine IgG1 and
is therefore frequently used for puriﬁcation of mouse mAbs
from, e.g., hybridoma supernatants. However, as bovine
serum is commonly used as hybridoma culture medium
supplement, the inherent strong afﬁnity of SPG for bovine
Ig can result in mixed immunoglobulin preparations which
may complicate the use of the reagent in immunoassay
applications [17, 18].
In this study, we have addressed the possibility of using
an afﬁbody molecule library based on a SPA domain
scaffold to isolate novel reagents with mouse IgG1 binding
properties. For the ﬁrst time, a large naı ¨ve 10
11 library was
constructed to use ribosome display (RD) in vitro selection
technology for identiﬁcation of afﬁbody binders, involving
an Escherichia coli secretion monitor protein-derived
sequence (SecM) for stabilization of afﬁbody–ribosome–
mRNA (ARM) ternary complexes during selection rounds.
The results demonstrate both a biotechnological utility and
interesting binding site preferences for identiﬁed in vitro
evolved binders, which are compared with the binding
epitopes for the naturally evolved SPA and SPG.
Materials and Methods
General
All the PCR and extension products were prepared using
proofreading Phusion DNA polymerase (Finnzymes) and
gel-puriﬁed oligonucleotide primers (MWG Biotech).
DNA restriction and modifying enzymes were from New
England Biolabs. PCR and extension products were puri-
ﬁed using the QIAquick DNA puriﬁcation kit (Qiagen).
Cleaved vectors were gel-extracted using the JETQUICK
gel extraction kit (Genomed). DNA sequences of all con-
structs were veriﬁed using an ABI Prism 3700 analyzer
(Applied Biosystems). RNA was prepared and puriﬁed as
described previously [19]. E. coli strain RR1DM15 was
used as host for cloning and Rosetta (DE3) for protein
expression.
Preparation of DNA Constructs
A plasmid pRD-ZWTdSalI was constructed in three steps.
First, the gene fragment coding for amino acids 221–308 of
M13-phage protein 3 (p3) was ampliﬁed from double stran-
ded M13K07 DNA using the primers p3-for (50-GACA
CACTCGAGCTCATATCAAGGCCAATCGTCTGACC-30;
underlined: XhoI recognition site) and p3-rev (50-CTTAT
CCAGACGGGCGTGCTGAAAGAATCAAGTTTGCCTT
TAGCG-30; underlined: sequence overlapping with SecM)
and a gene fragment encoding amino acids 175–195 of the
E.coliSecMwasampliﬁedfromE.coligenomicDNAusing
the primers SecM-for (50-CGCTAAAGGCAAACTTGATT
CTTTCAGCACGCCCGTCTGGATAAG-30; underlined:
sequence overlapping with p3) and SecM-rev (50-GTAGTA
GTCGACGCTCAGCCATTGATGATGTTGACCACTTT
GC-30; underlined: BlpI recognition site). In a second step,
using the overlapping sites, the SecM DNA fragment was
assembled with the p3 DNA fragment to yield p3-SecM.
Third, the p3-SecM fragment was inserted betweenthe XhoI
and BlpI sites of pET-23d-(ZWT)2 [20]. In order to introduce
a SalI recognition site between FLAG-tag and ZWT, a frag-
ment of pRD-ZWTdSalI was ampliﬁed using the primers
FLAG-for (50-TATACCATGGACTACAAAGATGACGA
TGATAAAACGTCGACCGTAGAC-30; underlined: NcoI
recognitionsite; italics: SalIrecognitionsite) andSecM-rev.
The ampliﬁed fragment was inserted between the NcoI and
XhoI sites of pRD-ZWTdSalI to yield pRD-ZWT. The vector
pRD-bla-H3 served as platform for library construction and
was prepared by amplifying a dummy DNA fragment
(fragment of bla gene) from pBR322 using primers Bla-for
(50-GTAGTAGTCGACCCACCCAGAAACGCTGGTG-30;
underlined: SalI recognition site) and Bla-rev (50-GTAGTA
GCTAGCCAATGCTTAATCAGTGAGGC-30;underlined:
NheI recognition site) and inserting it between the SalI and
NheI sites of pRD-ZWT. To prepare a SecM gene fragment
with reduced G/C content [21], a fragment of pRD-ZWT was
ampliﬁed using the primers p3-for and Secmut-rev (50-GTC
GACGCTCAGCTTAAGTTAAACGTTGAGGACCAGCA
CGAATACCTTGTGCTTGGCTTATCCAGACGGGCGT
G-30; underlined: BlpI recognition site; bold: mutated
positions) and inserted between the XhoI and BlpI sites of
pRD-bla-H3, yielding pRD2-bla-H3. For construction of
pRD2-(ZWT)2 and pRD2-ZTaq, the gene fragment coding
for a ZWT dimer, denoted (ZWT)2, was ampliﬁed from
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(50-GTAGTAGAGCTCTTCGGCGCCTGAGCATCATTT
AG-30; underlined: SacI recognition site), and the gene
fragment coding for ZTaq was ampliﬁed from pT7-(ZTaq)2
using the primers ZTaq-for (50-GTAGTAGTCGACCGTAG
ACAACAAATTCAACAAAGAACTGGGTTGG-30;u n d e r -
lined: SalI recognition site) and (ZTaq)2-rev. Both fragments
were inserted between the SalI and SacI sites of pRD2-bla-
H3 to yield pRD2-(ZWT)2 and pRD2-ZTaq, respectively.
Finally,pRD2-ZWT-ABDwasconstructedbyamplifyingthe
gene fragment coding for the albumin-binding domain
(ABD) from pAfﬁ1 [22] using the primers Abd-for (50-CAA
GTTCTCGAGTTTAGCTGAAGCTAAAGTCTTAGCTA
ACAGAG-30; underlined: XhoI recognition site) and Abd-
rev (50-CTAGAAGAGCTCACGTAAGGTAATGCAGCT
AAAATTTCATCTATC-30; underlined: SacI recognition
site) and inserting it between the XhoI and SacI sites of
pRD2-(ZWT)2.
Library Construction
The degenerate library primers Zlib-for (50-CCTGTAGTA
GTCGACCGTAGACAA CAAATTCAACAAAGAANN
KNNKNNKGCGNNKNNKGAGATCNNKNNKCTGCCG
AACCTGAAC-30; underlined: the overlap with Zlib-rev;
bold: the SalI recognition site; N stands for A, C, G, or T; K
stands for G or T) and Zlib-rev (50-CTTGTAGTAGCTAG
CAAGTTAGCGCTTTGGCTTGGGTCATCMNNTAAAC
TMNNGATGAAGGCMNNMNNTTGMNNMNNGTTCA
GGTTCGGCAG-30; underlined: the overlap with Zlib-for;
bold: the NheI recognition site; M stands for C or A) were
subjected to an extension reaction. In brief, 152 pmol of
each primer was extended using 4 ll of DNA polymerase
and 60 nmol dNTPs in a volume of 29 100 ll and during a
heat ramp from 98 to 72C, 0.1/s, which was repeated nine
times. After cleavage with SalI and NheI, 3.7 lgo f
extension product encoding randomized helices one and
two of the afﬁbody molecule scaffold and 9.1 lg of pRD-
bla-H3 were subjected to ligation using 150 Weiss units of
T4 DNA ligase in a 2 ml reaction volume that was dis-
tributed in 96 microtiter plate wells. The ligation products
were used to generate a pooled library PCR product. In
brief, 96 PCR reactions were performed using RD-for (50-
CCGCGAAATTAATACGAC TCACTATAGGGAGACC
ACAACGG-30) and RD-rev14 (50-TCTAGTTAAACGTT
GAGGACCAGCACGAATACCTTGTGCTTGGCTTATC
CAGACGGGCGTG-30) as primers, 30 cycles and 5 ll
ligation product as template, respectively. The use of the
RD-rev14 primer reduced the G/C content of the wild-type
SecM gene as described above for the construction of
pRD2-bla-H3. PCR products were pooled, and approxi-
mately 1.5 lg was used for in vitro transcription to yield
library RNA.
Real-Time PCR Analyses
Real-time PCR runs were performed in an iCycler system
(Bio-Rad). Per reaction, 12.5 ll Sybr Green mix (Bio-Rad)
and 10 pmol of each primer were mixed with template, and
the volume was adjusted to 20 ll. A program of 45 cycles
with an annealing temperature of 60 C was run, and
Ct-values were determined. For determining the library
size, RD-for and RD-rev3 (50-GTGCTGGCCTTGAGGG
CCAGCACGGATGCCTTGCG-30) served as primers; 1 ll
ligation, 0.1 ll ligation, and a concentration series of 1000,
100, 10, 1, and 0.1 pg pRD-ZWT were used as templates,
respectively. From the concentration series of pRD-ZWT,a
standard curve was calculated using linear regression. This
standard curve was used to obtain an estimate of the library
size, via the concentration of successfully ligated plasmids
in two dilutions of a library sample aliquot, using qua-
druplicate determinations.
DNA Sequencing
Library composition and selected clones after four rounds
of biopanning were analyzed by DNA sequencing on an
ABI Prism 3700 analyzer (Applied Biosystems) using
speciﬁc sequencing primers and Big Dye terminators
(Amersham Biosciences). Template was prepared from
randomly picked E. coli colonies by PCR ampliﬁcation or
rolling-circle plasmid ampliﬁcation using Phi29 DNA
polymerase (GE Healthcare).
Target Protein Preparation
Polyclonal human IgG (Pharmacia) was used as target
protein during enrichment studies, and the mouse IgG1
monoclonals ab 18447 (anti-para-nitrophenol, mAb1,
Abcam), biotinylated HDL 44 (anti-human Apolipoprotein
A1, mAb2, Mabtech), and 1-D1K (anti-human Interferon-c,
mAb3, Mabtech) were used as target proteins for library
selections. mAb1 and mAb3 were biotinylated using
EZ-Link
TM Sulfo-NHS-LC-biotin (Thermo Fisher Scien-
tiﬁc). A 75-fold molar excess of biotin was added to the
different immunoglobulins in PBS. The mixture was
incubated for 3 h on ice, and excess biotin was removed by
extensive dialysis. Stocks of target protein immobilized
on Streptavidin or NeutrAvidin-coated paramagnetic
Dynabeads
 M280 (Invitrogen) were prepared. The
amount of target immobilized was approximately 4 lg/mg
of beads as determined by SDS-PAGE. NeutrAvidin
(Thermo Fisher Scientiﬁc) was covalently immobilized on
tosylactivated Dynabeads
 M-280 according to manufac-
turer’s recommendations.
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Ribosome display was performed essentially as described
previously [19] with some modiﬁcations. Per reaction,
0.5 mg target and control beads (no target) were washed
four times with TBST (50 mM Tris–HCl, 150 mM NaCl,
0.05% Tween-20, pH 7.4) and blocked for 20 min with
WBT (50 mM Tris–acetate, 150 mM NaCl, 50 mM MgAc,
0.05% Tween-20) containing 0.5% BSA. In vitro transla-
tion (IVT) was performed using the PURESYSTEM

classic II (Cosmo Bio). Per reaction, 5 lg of mRNA tem-
plate, 25 ll solution A, 10 ll solution B, and 80 u RNasin

RNase inhibitor (Promega) were mixed, the volume was
adjusted to 50 ll, and the mixture was incubated for
20 min at 37C. IVT was stopped by transferring the
reaction to 220 ll ice-cold WBT containing 0.5% BSA and
2.5 mg/ml Heparin.
For enrichment studies, mRNA coding for ZWT-ABD or
ZTaq fused to a p3-SecM spacer was mixed in a ratio of
1:1000 (total amount of 5 lg) and used as template for
IVT. The stopped and stabilized IVT was incubated for 1 h
with 0.5 mg IgG-coated, blocked Dynabeads
 M280
Streptavidin. Beads were washed ﬁve times by gentle
pipetting before eluting the RNA (see below).
For library selections, 5 lg of library RNA was used as
input in IVT. During selection cycle 1, the IVT was
incubated with 0.5 mg mAb1-coated Dynabeads
 M280
NeutrAvidin for 1 h. During library selection cycle 2, the
IVT was ﬁrst incubated with 0.5 mg Dynabeads
 M280
NeutrAvidin for 1 h (pre-selection), immediately followed
by incubation with 0.5 mg mAb2-coated Dynabeads

M280 NeutrAvidin for 1 h (selection). During library
selection cycles 3 and 4, the IVT was ﬁrst incubated with
0.5 mg Dynabeads
 M280 Streptavidin for 1 h (pre-
selection), immediately followed by an incubation with
40 nM (cycle 3) or 4 nM (cycle 4) biotinylated mAb3 in
solution for 1 h. Biotinylated mAb3 was then captured with
0.5 mg Dynabeads
 M280 Streptavidin for 15 min. The
IVT was kept at 4C at all times. Beads were washes 2, 4,
6, and 10 times during library selection cycles 1, 2, 3, and
4, respectively (for an overview of selection parameters,
see Table 1). After washing, RNA was eluted from beads
with 50 mM EDTA in the presence of 50 lg/ml yeast
RNA, as described previously [19], followed by puriﬁca-
tion using the High Pure RNA Isolation Kit (Roche). To
avoid DNA contamination, columns were incubated for
10 min with DNaseI after having loaded the eluate. Half of
the eluted and puriﬁed RNA was immediately reverse
transcribed at a temperature of 55 C for 1 h using primer
RD-rev11 (50-TCTAGTTAAACGTTGAGGAC-30) and
AfﬁnityScript
TM reverse transcriptase (Stratagene). The
other half was saved as backup. In order to enter the next
selection cycle, the majority of the reverse transcription
product was PCR ampliﬁed using primers RD-for5 and
RD-rev9, and PCR product could directly be used as
template for in vitro transcription.
Protein Production and Puriﬁcation
In order to sequence and produce selected afﬁbody mole-
cules, reverse transcription products obtained after four
cycles of selection were PCR ampliﬁed using primers
Zsub-for2 (50-AGTAGGGAATTCCATATGGTAGACAA
CAAATTCAACAAAG-30; underlined: NdeI recognition
site) and Zsub-rev (50-TGATATGAGCTCGATTATTTCG
GCGCCTGAGCATCATTTAG-30; underlined: SacI rec-
ognition site) and the resulting product inserted between
the NdeI and SacI sites of the expression vector pAff8c
[23]. After sequencing, the most interesting clones in terms
of abundance and amino acid composition were expressed
as His6-tagged fusion proteins in E. coli strain Rosetta
(DE3). Cells were grown over night at 37Ci n1 0m lo f
TSB medium (30 g/l TSB) containing 50 mg/l kanamycin.
Fresh 250 ml TSB medium supplemented with 5 g/l yeast
extract (TSBY) and 50 mg/l kanamycin were inoculated
with 2.5 ml of over night culture, grown at 37 C to an
OD600 of 1.5, when gene expression was induced by
addition of isopropyl ß-D-thiogalactoside (IPTG; Apollo
Scientiﬁc Ltd) to a ﬁnal concentration of 1 mM. After 4 h
of induction, cultures were harvested by centrifugation
(2200 g, 10 min, 4C) and frozen at -20C. The next day,
cell pellets were suspended in 5 ml denaturing buffer (6 M
Table 1 Selection parameters
Cycle Beads Target Target
concentration (nM)
Pre-selection No. of washes Phase
1 NA mAb1 80 No 2 Solid
2 NA mAb2 80 Yes 4 Solid
3 SA mAb3 40 Yes 6 Solution
4 SA mAb3 4 Yes 10 Solution
Abbreviations: NA NeutrAvidin; SA Streptavidin; mAb1 anti-para-nitrophenol mIgG1 (Kappa); mAb2 anti-Apolipoprotein A1 mIgG1 (Kappa);
mAb3 anti-IFN-c mIgG1 (Kappa)
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NaH2PO4, 10 mM Tris–HCl, 104 mM NaCl, pH 8.0) and
disrupted by sonication. After centrifugation (35000g,
20 min, 4C), clear cell lysates were collected, and proteins
were puriﬁed in parallel using Talon Metal Afﬁnity Resin
(BD Biosciences) in combination with an ASPEC XL4
liquid handling robot (Gilson). Proteins were released with
elution buffer (8 M urea, 0.1 M NaCl, 29.6 mM HAc,
70.4 mM NaAc, 50 mM NaH2PO4, pH 5.0). The buffer
was changed to HBS, proteins were renatured by gel ﬁl-
tration, and puriﬁed proteins were separated by SDS-PAGE
using a NuPAGE
 Novex
 4–12% Bis–Tris gel (Invitro-
gen). The gel was stained using GelCode
 Blue Stain
(Thermo Fisher Scientiﬁc) according to manufacturer’s
recommendations. LMW-SDS Marker (GE Healthcare)
was used as molecular weight marker. Protein G C2–C3
fragment was produced in the periplasm of E. coli strain
O17 transformed with plasmid pK4C2C3 (kind gift from P.
Nilsson). 100 ml TSBY-medium was inoculated with a
single colony and grown over night at 37C. Cells were
harvested, the periplasmic content separated by osmotic
shock as described previously [24], and recombinant pro-
tein was puriﬁed using an IgG-Sepharose column and
0.2 M acetic acid for elution. The eluate fraction was fro-
zen, lyophilized, and suspended in HBS.
Biosensor Binding Studies
Binding properties of selected afﬁbody molecules were
analyzed using a Biacore
 2000 or 3000 instrument (GE
Healthcare). All measurements were performed in HBS-ET
(5 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005%
Tween 20, pH 7.4) at a ﬂowrate of 20 ll/min and 25C.
After each analyte injection, sensor chip surfaces were
regenerated by injection of 10 ll 0.1 M glycine–HCl,
0.5 M NaCl, pH 2.5, followed by 10 min stabilization time
unless otherwise stated. To correct for systematic devia-
tions and bulk buffer effects, both reference blank surface
signal and the signal obtained from the injection of a buffer
sample were subtracted from all sensorgrams [25]. For
candidate binder screening, the target mAb1, 2, and 3
(20 lg/ml in 10 mM NaAc pH 4.5) were separately
immobilized on three ﬂow cells of a CM5 sensor chip (GE
Healthcare) to ﬁnal densities of 3838 RU (mAb1), 3145
RU (mAb2), and 4085 RU (mAb3) using amine coupling
chemistry. Another ﬂow cell was activated and deactivated
to use as reference. Analyte concentrations were adjusted
to 1 lM in HBS-ET, and 80 ll samples were injected. For
afﬁnity determination, concentration series of selected
afﬁbody molecules from 1.95 nM to 8 lM were prepared,
and duplicates of 160 ll were ﬂowed in stepwise order at a
ﬂowrate of 40 ll/min over all four ﬂow cells. Assuming a
Langmuir 1:1 binding model or 1:1 binding model with
mass transport limitation (Zmab22_25 binding to mAb3), the
dissociation constant (KD), the association rate constant
(ka) and the dissociation rate constant (kd) were calculated
using BIAevaluation 3.2 software (GE Healthcare). For
binding analyses to a panel of different antibodies and
competition studies, a second CM5 sensor chip was pre-
pared onto which 1871 RU of Zmab25 and 1266 RU of
Zmab22_25 protein were immobilized on separate ﬂow cells
using amine coupling chemistry. The panel of injected
antibodies over Zmab25 and Zmab22_25 surfaces (100 nM)
included four mouse IgG1s: mAb2, mAb3, mouse IgG1:
HDL110 (anti-human apolipoprotein A1, Mabtech) and
mouse IgG1: 8F11 (anti-special AT-rich sequence-binding
protein 2 [26]), one mouse IgG2b: ab 18421 (anti-trinitro-
phenol, Abcam), one mouse–human chimera: Inﬂiximab
(anti-TNFa, Schering-Plough), one human myeloma IgG1:
GTX76676 (GeneTex) and one mouse IgG1(k) S1-68.1
(BD Biosciences). For competition studies, a 10 nM solu-
tion of mAb3 was incubated with 100 nM, 1, 10 lMo r
without a recombinant two-domain protein G construct
(C2–C3) for 30 min at room temperature, and 100 ll was
subsequently injected over the Zmab25 surface. C2–C3
(1 lM) was also injected over the target mIgG1 chip sur-
faces to conﬁrm binding to mIgG1. For analysis of Zmab25
or protein G C2–C3 domain interaction with fetal bovine
serum (FBS), a third CM5 sensor chip was prepared onto
which 488 RU of protein G C2–C3 and 1817 RU of Zmab25
were immobilized on separate surfaces, and 100 ll of 10%
FBS (Gibco) or 10% FBS and 133 nM mAb3 were ﬂowed
over both surfaces. Sensor chip surfaces were regenerated
with 10 ll 0.1 M glycine–HCl pH 2.0. For species selec-
tive immunoglobulin binding analysis of eluate fractions
from afﬁnity puriﬁcation studies, a fourth CM5 sensor chip
was prepared onto which 5330 RU of an anti-cow IgG
antibody (ab6934, Abcam) or 5354 RU of an anti-mouse Ig
antibody (P0447, Dako) was immobilized on separate
surfaces. 100 ll of neutralized afﬁnity puriﬁcation eluate
fractions was ﬂowed over both surfaces.
Isotyping of Antibodies
An IsoStrip Mouse Monoclonal Antibody Isotyping Kit
(Roche) was used for typing of antibody heavy and light
chains when not speciﬁed in their respective data sheets
provided by the supplier.
Papain Cleavage of Antibodies
To obtain Fab and Fc fragments of mAb3, 100 lg of the
antibody was cleaved with papain immobilized on agarose-
beads (Thermo Fisher Scientiﬁc) according to manufac-
turer’s recommendations.
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A HiTrap
TM Protein G HP column with 1 ml bed volume
coupled with more than 2 mg recombinant protein G
lacking the albumin-binding region was bought from GE
Healthcare. The NHS-activated agarose matrix of a second
HiTrap
TM HP Column with 1 ml bed volume (GE
Healthcare) was coupled with approximately 5 mg of
Zmab25 according to manufacturer’s recommendations. All
puriﬁcation studies were performed on an A ¨kta Explorer
(GE Healthcare) at ﬂow rates of 0.1 or 0.5 ml/min (sample
loading) or 1 ml/min (washing/elution) using TST (25 mM
tris(hydroxymethyl)aminomethane, 1 mM EDTA, 200 mM
sodium chloride, and 0.05% v/v Tween20, pH 8.0) as
running buffer. The following samples were loaded on the
protein G or Zmab25 columns or both (see Results section):
(1) 50 lg of mAb3 after papain cleavage in 1 ml TST; (2)
5 ml TST supplemented with 10% FBS (Gibco); (3)
100 lg of mAb3 in 5 ml TST supplemented with 10%
FBS; (4) 100 lg of mAb 8F11 in 5 ml TST supplemented
with 10% FBS. The chromatography system was equili-
brated with TST, samples were injected and after the ﬂow-
through had passed, the column was washed with 3 ml
5 mM ammonium acetate pH 6, and bound protein was
eluted with 0.5 M acetic acid, pH 2.2. For sample (1),
eluate fractions of 0.5 ml were collected, pooled, imme-
diately frozen to -80C, lyophilized, and taken up in
reducing loading buffer for SDS-PAGE analysis. For
samples (2–4), four eluate fractions of 0.5 ml were pooled,
one half was neutralized by adding 760 ll1 M
tris(hydroxymethyl)aminomethane pH 9.0 and dialyzed
extensively against HBS-ET for subsequent biosensor
analysis. The other half was lyophilized and suspended in
100 ll reducing loading buffer for SDS-PAGE analysis.
SDS-PAGE and Western Blot Analysis of Afﬁnity
Puriﬁcation Studies
Sample (1)-derived fractions were separated together with
the SeeBlue
 Plus2 Pre-Stained Standard (Invitrogen)
by SDS-PAGE under reducing conditions using two
NuPAGE
 Novex 4–12% Bis–Tris gels (Invitrogen).
200 V was applied for 45 min in MES running buffer at
4C. Separated proteins were transferred on two PVDF
membranes with 0.45 lm pore size (Invitrogen) for 1 h at
30 V and 4C. Membranes were blocked for 1 h with 5%
milk powder in de-ionized water supplemented with 0.5%
v/v Tween 20 and incubated with either HRP-conjugated
goat polyclonal antibody to mouse IgG Fc (F(ab)2 frag-
ment, ab 5879, Abcam) or goat polyclonal to mouse IgG
F(ab)2 (F(ab)2 fragment, ab 5887, Abcam) diluted 1:5000
in blocking solution. The membranes were subsequently
washed with TBS supplemented with 0.5% v/v Tween 20
and developed using the TMBM-500 substrate (MOSS).
Sample (2), (3), or (4)-derived fractions (4 ll applied
sample, 4 ll ﬂow-through fraction, 10% of the eluate
fraction, respectively) were separated by SDS-PAGE using
a Mini-PROTEAN
 TGX
TM Any kD gel (Bio-Rad) under
reducing conditions at 100 V for 75 min at 4C. The gel
was ﬁxed in 40% v/v ethanol and 10% v/v acetic acid and
stained with GelCode
 Blue Stain (Thermo Fisher Scien-
tiﬁc) according to manufacturer’s recommendations.
Results
Ribosome Display System Design and Evaluation
A plasmid construct denoted pRD was constructed to use
as assembly vector and PCR ampliﬁcation template of
linear expression cassettes for RD-mediated selection of
binding proteins from libraries of afﬁbody molecules
(Fig. 1a). Following sequences corresponding to a standard
T7 RNA polymerase promoter (PT7), a Shine Dalgarno
(SD) ribosomal-binding site and a FLAG peptide encoding
sequence, restriction sites allowing for introduction of gene
fragments encoding different model proteins or afﬁbody
molecule library members were incorporated for in-frame
fusion to a downstream element encoding a bipartite spacer
and ribosome tunnel spanning sequence. The ﬁrst part of
this sequence corresponds to a stretch of 88 residues from
the bacteriophage M13 protein 3 (p3 spacer), previously
utilized as spacer element in RD selections [19]. This
sequence was linked to a second element corresponding to
a 21-residue stretch (aa 175 to 195) of the E. coli SecM,
earlier reported to interact with the ribosome tunnel and
capable of providing stable peptide–ribosome–mRNA ter-
nary complexes even when followed by a downstream
in-frame termination codon [27–30]. Here, the natural stop
codon in the SecM gene was, however, replaced by an
AGA triplet, corresponding to a rare arginine codon in
E. coli to possibly further avoid disruption of ternary
complexes during selection.
For system evaluation, test enrichment experiments
were performed involving an mRNA mixture, prepared
from mRNA obtained after in vitro transcription using PCR
product expression cassettes encoding the model proteins
ZWT-ABD (IgG and HSA binding fusion protein; Fig. 1b)
or ZTaq (afﬁbody molecule binding to Taq DNA poly-
merase [31]; Fig. 1c) fused to the p3-SecM spacer. Two
rounds of RD selection were performed using human IgG-
coated beads for enrichment of the rare IgG-binding ZWT-
ABD encoding constructs present in an initial 1000-fold
molar excess of Taq DNA polymerase binder encoding
control constructs, and the results monitored via analysis of
PCR products obtained after post-selection RT-PCR. An
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was repeatedly seen (Fig. 2), indicating that the system was
functional.
An afﬁbody molecule library was constructed based on a
previously described randomization strategy of the Z
domain, involving an unbiased combinatorial NNK codon-
based variegation of 13 surface-located positions in helices
one and two of the three-helix bundle scaffold [5]. Through
replacement of a previously inserted dummy DNA frag-
ment in the pRD vector for a primer extension product
encoding the library of randomized helices one and two, a
plasmid format library with the size of 10
11 was obtained
(Fig. 1d), as determined via quantiﬁcation of ligation
product DNA by real-time PCR (Fig. 3). Transformation of
bacteria with an aliquot of the library allowed for a clone-
based analysis of the library quality, which showed that 62
out of 87 sequenced clones (71%) were correctly assem-
bled and that remaining 25 clones (29%) contained
nucleotide insertions and/or deletions at different positions.
The plasmid format of the library served as template pool
for the generation of linear expression cassettes by PCR
(Fig. 1 and Material and Methods section).
Selections
In order to direct a selection of binders towards general
murine IgG1-speciﬁc epitopes, three different mIgG1 anti-
body proteins (mAbs 1–3) were used as targets during
selections. In a ﬁrst cycle, an anti-para-nitrophenol mono-
clonal antibody (mAb1) was used, followed by an anti-
human Apolipoprotein A1 mAb (mAb2) in cycle 2, and an
anti-human Interferon-c mAb (mAb3) in cycles 3 and 4.
The selection stringency was gradually increased by
introducing a pre-selection step using non-target containing
beads in cycle 2, and gradually decreasing target protein
concentration and increasing the number of washing steps
(Table 1). Analysis of 206 selected clones obtained
Fig. 1 Afﬁbody molecule ribosome display system design. Sche-
matic overview of the constructed ribosome display system. a An
expression cassette was assembled in a vector denoted pRD,
containing a T7 promoter, a Shine Dalgarno sequence and a FLAG
epitope encoding sequence, followed by a cloning window and a
sequence encoding a bipartite spacer element containing a 88-residue
phage M13 protein 3 sequence (p3 spacer) followed by a 21-residue
element derived from the E. coli SecM. The Arg residue (in brackets)
indicates the extension of the SecM motif by this codon during PCR
ampliﬁcation prior to transcription; b, c for initial enrichment studies,
gene fragments encoding either ZWT-ABD or ZTaq proteins were
inserted in the expression cassette as indicated; d for afﬁbody
molecule library construction, two oligonucleotides (Zlib-for and
Zlib-rev) encoding randomized helices one and two of the three-helix
bundle scaffold were extended together utilizing mutually overlap-
ping sequences for annealing, followed by cloning into the expression
cassette where the extension products replaced a dummy fragment. A
gene fragment encoding helix three was here already present in the
pRD vector. Restriction sites and annealing sites for some of the
oligonucleotide primers used during cloning, reverse transcription and
PCR work are indicated (see text for details)
Fig. 2 Results from initial enrichment experiments. Agarose gel
electrophoresis analysis of PCR products obtained using DNA
templates produced after reverse transcription of mRNA recovered
after different numbers of rounds of IgG afﬁnity selection of ternary
complexes containing ZWT-ABD proteins. Lane 1: marker DNA; lane
2: PCR product obtained after reverse transcription and ampliﬁcation
of an initial 1:1000 mixture of ZWT-ABD mRNA in a background
of ZTaq mRNA; lane 3: PCR product obtained after a ﬁrst round of
enrichment; lane 4: PCR product obtained after a second round of
enrichment. Arrows indicate marker DNA bands and the expected
sizes for amplicons corresponding to ampliﬁcation of ZWT-ABD and
ZTaq constructs, respectively
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showed that three library members (Zmab22,Z mab25, and
Zmab26) had been more enriched than other members and
appeared 173 (Zmab22), 13 (Zmab25), and 2 times (Zmab26),
respectively. Furthermore, a hybrid clone denoted
Zmab22_25, probably created by recombination of Zmab22 and
Zmab25 during post-selection cloning work, was found three
times (Fig. 4). Clone Zmab22 contains two cysteines that
give rise to oligomerization (dimers and trimers) under
non-reducing conditions as conﬁrmed by non-reducing
SDS-PAGE analysis (data not shown). In addition, clones
corresponding to the wild-type Z domain sequence
appeared, presumably corresponding to a contamination
during the selection.
Binding Studies
Binding to mAb1, mAb2, and mAb3 was analyzed using
surface plasmon resonance where the three variants Zmab22,
Zmab25, and Zmab22_25 all showed binding to all three mAb,
whereas the Zmab26 variant did not bind any of the three
investigated antibodies under these conditions. For deter-
mination of binding afﬁnities, serial dilutions of the Zmab22,
Zmab25, and Zmab22_25 variants ranging from 1.95 nM to
8 lM were injected over sensor chip surfaces coated with
mAb1, mAb2, and mAb3, respectively. The results showed
that the three afﬁbody variants bind the three different
mIgG1 antibodies mAb1–3 with dissociation constants
(KD) of 1.3 lM, 487, 8.1 nM (Zmab22); 371, 190, 19.2 nM
(Zmab25), and 191, 125, 1.8 nM (Zmab22_25) (Fig. 5).
To further investigate the selectivity in binding, a
reversed format was used in which the Zmab22,Z mab25, and
Zmab22_25 variants were covalently immobilized onto
sensor chip surfaces and analyzed for binding to various
injected mouse and human IgG antibodies. The Zmab25
variant bound the antibody targets used during selection as
well as two other mIgG1/kappa light chain antibodies not
used as targets during selection, indicating a broad mIgG1
binding capacity. The binding responses obtained from the
two non-target mIgG1/kappa mAbs included here were
lower than those obtained from the antibodies used as
targets during selection, indicating a lower afﬁnity of
Zmab25 for these particular antibodies (see Discussion).
Also, as judged from the shape of the traces, the inter-
action with the non-target mIgG1 8F11 mAb shows sig-
niﬁcantly slower off-rate kinetics than seen for the other
non-target mIgG1 mAb included in the analysis
(HDL110). Interestingly, a mouse IgG2b/kappa isotype
control, a puriﬁed myeloma-derived human IgG1 antibody
and a chimeric mouse–human IgG1 (murine Fv part)
where not recognized by the Zmab25 variant, indicating a
narrow binding preference for murine IgG1. Notably, a
mouse IgG1 isotype control mAb containing a lambda
light chain was not recognized under these conditions,
implying a possible inﬂuence also from the light chain
type on binding (Fig. 6). The Zmab22 and Zmab22_25 vari-
ants, however, did either not show any or only a limited
binding ability in this format, suggesting that the covalent
immobilization via primary amines affected the molecular
properties.
Fig. 3 Real-time PCR analysis of the library size. The real-time PCR
threshold cycle (Ct) values obtained from ﬁve different pRD-ZWT
template amounts (0.1, 1, 10, 100, and 1000 pg) were plotted in a
logarithmic scale. The data were ﬁtted using linear regression (gray
dashed line) and from the regression line, the amount of successfully
ligated plasmids in two different dilutions of the library ligation
reaction was determined (quadruplicates, ﬁlled circles). A low
estimate of the library size, calculated using the mean value from
the quadruplicate referring to the more diluted sample, was approx-
imately 1 9 10
11
Fig. 4 Sequences of selected afﬁbody molecules. Deduced amino
acid sequences of in total 206 sequenced clones appearing two or
more times. The wild-type Z domain sequence is shown, with dots
over the positions randomized to construct the library and the three
alpha helices of the scaffold are boxed. The numbers to the right
indicate the number of times with which a particular library member
appeared among the sequenced clones
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A biosensor-based binding competition assay was per-
formed as an attempt to roughly map the binding site for the
Zmab25 variant on mIgG1. Here, a recombinantly produced
fragment of the Ig binding protein SPG containing two Ig
binding domains (C2–C3) was used. SPG is known to bind
IgG in a species-dependent manner both to CH1 domains in
Fabregions[32]andtotheCH2–CH3domain interface inFc
[33]. In the competition assay, the binding between sensor
chip immobilized Zmab25 protein and mAb3, used either as
free monoclonal antibody or after pre-incubation with dif-
ferent molar excesses of SPG fragment were analyzed. The
results showed that a mixing of the mAb3 with a 100-fold
molar excess of SPG fragment signiﬁcantly reduced the
mAb3 binding to Zmab25, and that a mixing with a 1000-fold
molar excess of SPG fragment almost completely blocked
the binding (Fig. 7). This indicated that the binding site for
Zmab25 on mouse IgG1 is located at a site sterically inter-
fering with SPG at one of the two binding sites of SPG. To
prepareasamplethatcouldbeusedtoexcludeoneofthetwo
sites, mAb3 was enzymatically digested with papain,
yielding a mixture of Fc and Fab fragments. After applying
this sample onto an afﬁnity column containing Zmab25
ligands, the Fab fragments were selectively captured and
eluted from the column (Fig. 8), indicating that the selected
Fig. 5 Biosensor analysis of afﬁbody molecule variants Zmab22,
Zmab25, and Zmab22_25 binding to mAb1, mAb2, and mAb3. Panels
show recorded concentration dependent responses after injection of
afﬁbody molecules Zmab22 (a–c),Z mab25 (d–f), and Zmab22_25 (g–i)
over sensor chip immobilized antibodies mAb1 (a, d, g), mAb2 (b, e,
h), or mAb3 (c, f, i). Biosensor sensorgram traces were obtained
during injection of a series of concentrations ranging between 4 lM
and 125 nM (a, b), 1 lM and 31 nM (c, d, e), 250 and 7.8 nM (f), 500
and 16 nM (g, h) as well as 125 and 4 nM (i) of monomeric afﬁbody
variants produced as hexahistidyl (His6) fusion proteins
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SPG at its binding site on the CH1 domain of mouse IgG1
Fab.
Afﬁnity Chromatography
As indicated by the successful column-based recovery of
the Fab fragment, one possible biotechnological use of the
Zmab25 afﬁbody protein could be as afﬁnity ligand in the
recovery of mouse IgG1 mAbs from hybridoma culture
supernatants. However, such feed stocks frequently con-
tain, in addition to the secreted mAb, also bovine immu-
noglobulins originating from the hybridoma growth
medium supplement FBS. Thus, bovine Ig can become
co-puriﬁed with mAbs using group speciﬁc afﬁnity ligands
with broad Ig binding spectra, such as wild-type protein A
or G. Such contamination has been shown to frequently
contribute to false-positive readouts in sandwich immu-
noassays involving human sera samples containing human
anti-bovine IgG antibodies (HABIAs) [18]. To investigate
if the Zmab25 afﬁbody protein showed any binding to bovine
Ig, a sample of 10% FBS was injected over both a Zmab25
and a protein G C2–C3 domain reference sensor chip
surface. Interestingly, whereas the reference surface
showed a signiﬁcant response, no binding response was
observed for the Zmab25 surface, indicating that bovine Ig,
or any other FBS component, was not recognized by the
variant selected using mouse IgG1 as target (Fig. 9a). Only
after spiking of the 10% FBS sample with mouse IgG1
Fig. 6 Binding studies of Zmab25 with a panel of eight antibody
samples. Zmab25 was recombinantly produced as a hexahistidyl (His)6
fusion protein, IMAC puriﬁed and immobilized onto a CM5 sensor
chip surface and various immunoglobulin samples of a common
100 nM concentration injected. Response curves obtained on samples
ﬂowed over the Zmab25 surface are labeled as follows: anti-human
interferon-c mIgG1 mAb3 (gray diamonds), anti-human apolipopro-
tein mIgG1 mAb2 (gray squares), anti-human apolipoprotein mIgG1
HDL110 (gray circles), and anti-special AT-rich sequence-binding
protein 2 mIgG1 8F11 (gray triangles). Responses obtained for anti-
trinitrophenol mIgG2b ab18421, anti-TNFa mouse–human chimera
Inﬂiximab, human myeloma IgG1 GTX76676, and mIgG1(k) S1-68.1
can be seen as ﬂat traces at the bottom of the graph. In a parallel
experiment, also the mAb1 reagent was found to be recognized by the
Zmab25 variant in this format (data not shown)
Fig. 7 Mapping of Zmab25 binding site by competitive binding
analyses. Possible binding sites on mouse IgG1 for the Zmab25 variant
were mapped using a competitive binding analysis employing an
immunoglobulin binding protein with known binding sites.
a Schematic ﬁgure showing an IgG antibody protein with its different
regions and the binding sites for SPG in Fc and Fab, respectively,
indicated. b Biosensor sensorgrams resulting from duplicate injec-
tions of 10 nM mAb3 alone (gray diamonds); mAb3 in a 100 nM
(gray squares), 1 lM( gray circles), or 10 lM( gray triangles)
solution of the recombinant two-domain protein G construct (C2–C3)
over a sensor chip surface containing the Zmab25 variant
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obtained, suggesting that the Zmab25 variant could be used
for selective afﬁnity recovery of mouse IgG1 from samples
also containing bovine Ig and high concentrations of
bovine serum albumin originating from added FBS
(Fig. 9a). To investigate this possibility, afﬁnity columns
containing either SPG or Zmab25 ligands were in separate
experiments loaded with 5 ml samples of 10% FBS alone
or 10% FBS spiked with 100 lg of mAb3, followed by
washing and elution. Analysis of eluates from both
experiments by SDS-PAGE under reduced conditions
showed that the SPG column had retained proteins corre-
sponding to characteristic sizes of heavy and light chains of
immunoglobulins, approximately 25 kDa for light chains
and 50–60 kDa for heavy chains, irrespective of the sample
used (Fig. 9b). In contrast, the Zmab25 column eluates only
contained such bands when the mAb3-spiked sample was
applied, indicating a species selective capture of mouse
IgG1. To investigate if also a murine IgG1 monoclonal
antibody not used as target during selection and with lower
apparent afﬁnity for Zmab25 could be recovered, the
experiment was repeated with a sample of 10% FBS spiked
with 100 lg of mAb 8F11. Again, proteins corresponding
to characteristic sizes of heavy and light chains were
selectively retained (Fig. 9b). To conﬁrm these ﬁndings,
the compositions of pH neutralized eluates obtained from
the mAb3 or mAb 8F11-spiked samples were further
analyzed by biosensor technology, utilizing antibodies of
anti-cow IgG or anti-mouse Ig speciﬁcities immobilized on
separate sensor chip surfaces. In this analysis, signiﬁcant
binding responses to both surfaces were obtained with the
SPG column eluate, showing that this eluate contained both
bovine and mouse Ig. In contrast, the eluates from the
Zmab25 column both only gave a response to the anti-mouse
Ig surface (Fig. 9c). Taken together, this demonstrated the
applicability of the Zmab25 afﬁbody molecule as ligand for
selective capture of two different mouse IgG1 mAbs from a
sample resembling a supernatant from hybridoma cultured
in medium containing FBS.
Discussion
This study describes the selection of novel proteinaceous
afﬁnity ligands to mouse IgG1 by RD technology. A
binding experiment performed with the most thoroughly
investigated variant Zmab25 showed that the resulting
binding proﬁle for this ligand, among the tested immuno-
globulin variants, was restricted to mouse IgG1 only. This
corresponds to very narrow binding spectra involving only
the immunoglobulin class used for selection. This is in
contrast to the widely used natural immunoglobulin bind-
ing proteins SPG and SPA which both show much broader
binding spectra in terms of Ig origin and subclass identity,
and which have been evolved under the pressure of com-
plex biological and immunological aspects in several dif-
ferent hosts. It is interesting to note that although the
scaffold upon which the afﬁbody binding molecule class is
based on is derived from SPA, showing a species-depen-
dent and well-characterized binding to the CH2–CH3
region in Fc and to some VH domain families, no prefer-
ence for the corresponding region in the mouse antibody
targets was observed in this study. In fact, an attempt to
map the binding site for the Zmab25 binder indicated that an
epitope on Fab was recognized, overlapping with the SPG-
binding site. The structure of the co-complex between a
single SPG domain and human IgG1 Fab has been deter-
mined by X-ray crystallography and shows that the SPG
domain with its mixed beta-sheet/alpha-helix secondary
structure elements content predominantly interacts with the
Fig. 8 Western Blot analysis of mAb3 Fab fragment capture after
papain cleavage. The mouse IgG1 mAb3 was papain-digested and the
sample applied on a HiTrap
TM HP column with Zmab25 immobilized
as ligand for capture of the targets for the ligand. Panel a was stained
with a polyclonal goat anti-mouse IgG Fc HRP conjugate. Lane 1:
SeeBlue
 Plus2 Pre-Stained standard; lane 2: mAb3 sample before
cleavage; lane 3: mAb3 sample after cleavage; lane 4: column ﬂow-
through fraction; lanes 5, 6: eluate fractions. Panel b was stained with
a polyclonal goat anti-mouse IgG F(ab)2 HRP conjugate. Lane 1:
SeeBlue
 Plus2 Pre-Stained standard; lane 2: mAb3 sample before
cleavage; lane 3: mAb3 sample after cleavage; lane 4: column ﬂow-
through fraction; lanes 5, 6: eluate fractions. The black arrows to the
left indicate molecular weights in kilo Dalton (kDa)
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through main chain atom-mediated beta-zipper interac-
tions, which in turn has been proposed to contribute to the
observed promiscuity in terms of binding to Fab fragments
derived from antibodies of different origin and subclass
identities [32, 34]. The indication from the competition
experiment that the binding site for the Zmab25 variant
resides in the Fab CH1 domain together with the binding
preference for mouse IgG1 over mouse IgG2b is notable,
considering the high sequence homology between murine
Fab CH1 domains. However, in a study by Sheriff et al.
[35], the three-dimensional structures of CH1 domains
Fig. 9 Binding studies of Zmab25 or protein G with fetal bovine serum
and species selective afﬁnity recovery of two monoclonal antibodies.
a 10% FBS was ﬂowed over a Zmab25 (gray solid trace) or protein G
C2–C3 fragment (SPG) (black dashed trace) BIAcore biosensor
surface. For comparison, a sample containing 10% FBS spiked with
mouse IgG1 mAb3 was also ﬂowed over the Zmab25 surface (black
solid trace). b: SDS-PAGE analysis (reducing conditions) of samples,
ﬂow-through (FT), and eluate (E) fractions from afﬁnity chromatog-
raphy experiments using either a protein G (SPG) column or a Zmab25
column, and samples of 10% FBS only (lanes 1–6) or 10% FBS with
in-spiked mouse IgG1 mAb3 (lanes 7–12) or 10% FBS with in-spiked
mouse IgG1 8F11 (lanes 13–15). M LMW-SDS molecular weight
marker; lane 1: 10% FBS sample; lane 2: SPG column, FT; lane 3:
SPG column, E; lane 4: 10% FBS sample; lane 5:Z mab25 column, FT;
lane 6:Z mab25 column, E; lane 7: 10% FBS ? mAb3 sample; lane 8:
SPG column, FT; lane 9: SPG column, E; lane 10: 10%
FBS ? mAb3 sample; lane 11:Z mab25 column, FT; lane 12:Z mab25
column, E; lane 13: 10% FBS ? mAb 8F11 sample; lane 14:Z mab25
column, FT; lane 15:Z mab25 column, E. The black arrows to the right
indicate nominal molecular weights of antibody heavy and light
chains, respectively. The numbers to the left indicate molecular
weights in kilo Dalton (kDa). c Results from a biosensor analysis of
pH neutralized eluates from the SPG and Zmab25 columns, originating
from the use of the 10% FBS sample containing in-spiked mAb3
(1–4) or mAb 8F11 (5, 6). On separate ﬂow cell surfaces, anti-cow
IgG and anti-mouse Ig antibodies were immobilized, and samples
were injected. (1) black solid trace SPG column eluate, anti-cow IgG
surface; (2) black dashed trace SPG column eluate, anti-mouse
Ig surface; (3) gray solid trace Zmab25 column eluate, anti-cow IgG
surface; (4) gray dashed trace Zmab25 column eluate, anti-mouse
Ig surface; (5) black dotted trace Zmab25 column eluate, anti-cow IgG
surface; (6) gray dotted trace Zmab25 column eluate, anti-mouse Ig
surface
274 Mol Biotechnol (2011) 48:263–276
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subclasses (IgG1, IgG2a, IgG2b, and IgG3) were compared,
and although similar in sequence, local structural differ-
ences were observed, which may explain the observed
binding characteristics of Zmab25.
Furthermore, a difference in binding strengths to dif-
ferent individual mouse IgG1 clones were also observed,
including the three mAbs used during the selection. This
could possibly be explained by differences in post-trans-
lational modiﬁcation or allotypic variance. However, the
comparison of relative afﬁnities to target and non-target
antibodies based on the analysis where the mAb analytes
were injected over a surface containing the Zmab25 afﬁnity
ligand should be done with some caution. The comparison
may have been inﬂuenced by difﬁculties in estimating the
true analyte (mouse mAb) concentration in the injected
sample. As shown in this study, preparations of mouse
monoclonals puriﬁed by conventional methods may con-
tain an unknown level of FBS-derived bovine Ig, whose
presence may contribute to an overestimation of the mAb
protein concentration as determined by spectroscopic
measurements or other methods. Actually, contamination
of mAbs with bovine immunoglobulin originating from the
culture medium supplement FBS is a general concern in
monoclonal antibody production. To date, this has been
addressed by the screening for FBS containing low natural
levels of bovine immunoglobulin or via protein G-medi-
ated Ig depletion [17]. The observed discrimination
between murine IgG1 and bovine serum immunoglobulins
by the Zmab25 afﬁbody ligand developed in this study, in
combination with its ease of recombinant production,
envision the use of Zmab25 as an alternative solution for
selective murine IgG1 recovery from different hybridoma
culture media.
The dominant afﬁbody variant found after four selection
cycles was Zmab22 containing two cysteines. It could be
speculated that this could result in the formation of an
intrachain disulﬁde, contributing to increased stability of
the protein, in turn leading to dominance during selection.
However, assuming a native-like fold of this afﬁbody
variant, the distance between these cysteins would be
approximately 15 A ˚, by far exceeding the ca. 2 A ˚ regarded
as a productive distance for disulﬁde formation [36].
Rather, the observation that the Zmab22 variant can form
both dimeric and trimeric assemblies suggest that the two
cysteines are accessible for inter- rather than intra-chain
linkages. Hypothetically, the enrichment of Zmab22 may in
fact have been driven by avidity effects due to oligomeri-
zation during the panning procedure. During the IVT pro-
cedure in RD, several ribosomes may line up on the very
same mRNA molecule (polysomes) [37]. Thus, it is pos-
sible that two or more individual Zmab22 polypeptides,
emerging from separate but closely positioned ribosomes,
may have become linked during the procedure and
favoured during selections due to avidity effects in target
binding.
The dominance of Zmab22 may have inﬂuenced nega-
tively on the selection of other good binders devoid of
cysteines, potentially present in the library. Such clones
could be expected to increase in number during early
cycles while the target amount still is non-limiting, while
later become gradually outcompeted by a dominant clone.
In fact, some clones which appeared only once after
selection cycle 4, and thus potentially could correspond to
such clones, were produced and tested for mIgG1 binding.
However, they were all found to be either non-binders or
very weak binders (data not shown). This may indicate that
potentially good binders were not missed due to dominance
by the Zmab22 clone.
The described study represents the ﬁrst study where
afﬁbody molecule libraries have been explored in con-
junction with RD technology. One of the beneﬁts with this
display technology is that transformation of cells is not
needed for either the library construction or during the
selection process, which facilitates the generation of large
libraries. The library size in this study was determined to
10
11 using Q-PCR, corresponding to a complexity 30- to
2000-fold larger than previously described naı ¨ve afﬁbody
molecule libraries [5, 9]. The design of the expression
cassette in the present RD system allowed for an optional
extension of a standard spacer element by a ribosome
tunnel interacting SecM sequence in the translated gene
product. In the development phase of the system, this
element was shown to result in higher yields of recovered
RT-PCR products after selection, interpreted as a capability
to contribute to the stabilization of formed ternary com-
plexes under the experimental conditions used. This may
allow for future development of alternative selection pro-
tocols involving higher temperatures or different chemical
compositions of selection buffers, without causing complex
disintegration.
In conclusion, this study shows that RD in vitro
selection technology is a viable option for constructing
and working with large afﬁbody molecule libraries. Fur-
ther, a novel mouse IgG1 Fab binding reagent is described
which should be a valuable tool in biotechnology
applications.
Acknowledgments We are grateful to Peter Nilsson and Anna
Perols for providing reagents and technical advice. This study
was supported by a grant from The Swedish Research Council (Grant
No. 50548301).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Mol Biotechnol (2011) 48:263–276 275
123References
1. Lin, H., & Cornish, V. W. (2002). Screening and selection
methods for large-scale analysis of protein function. Angewandte
Chemie International Edition in English, 41, 4402–4425.
2. Binz, H. K., Amstutz, P., & Pluckthun, A. (2005). Engineering
novel binding proteins from nonimmunoglobulin domains.
Nature Biotechnology, 23, 1257–1268.
3. Gebauer, M., & Skerra, A. (2009). Engineered protein scaffolds
as next-generation antibody therapeutics. Current Opinion
Chemical Biology, 13, 245–255.
4. Nygren, P. A., & Skerra, A. (2004). Binding proteins from
alternative scaffolds. Journal of Immunological Methods, 290,
3–28.
5. Nord, K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M., &
Nygren, P. A. (1997). Binding proteins selected from combina-
torial libraries of an alpha-helical bacterial receptor domain.
Nature Biotechnology, 15, 772–777.
6. Nygren, P. A. (2008). Alternative binding proteins: Afﬁbody
binding proteins developed from a small three-helix bundle
scaffold. FEBS Journal, 275, 2668–2676.
7. Nilsson, F. Y., & Tolmachev, V. (2007). Afﬁbody molecules:
New protein domains for molecular imaging and targeted tumor
therapy. Current Opinion Drug Discovery and Development, 10,
167–175.
8. Zielinski, R., Lyakhov, I., Jacobs, A., Chertov, O., Kramer-Marek,
G., Francella, N., et al. (2009). Afﬁtoxin-a novel recombinant,
HER2-speciﬁc, anticancer agent for targeted therapy of HER2-
positive tumors. Journal of Immunotherapy, 32(8), 817–825.
9. Gronwall, C., Jonsson, A., Lindstrom, S., Gunneriusson, E.,
Stahl, S., & Herne, N. (2007). Selection and characterization of
Afﬁbody ligands binding to Alzheimer amyloid beta peptides.
Journal of Biotechnology, 128, 162–183.
10. Jonsson, A., Wallberg, H., Herne, N., Stahl, S., & Frejd, F. Y.
(2009). Generation of tumour-necrosis-factor-alpha-speciﬁc afﬁ-
body1 molecules capable of blocking receptor binding in vitro.
Biotechnology and Applied Biochemistry, 54, 93–103.
11. Lofdahl, P. A., Nord, O., Janzon, L., & Nygren, P. A. (2009).
Selection of TNF-alpha binding afﬁbody molecules using a beta-
lactamase protein fragment complementation assay. New Bio-
technology, 26, 251–259.
12. Chiarella, P., & Fazio, V. M. (2008). Mouse monoclonal anti-
bodies in biological research: Strategies for high-throughput
production. Biotechnological Letters, 30, 1303–1310.
13. Stahl, S., & Nygren, P. A. (1997). The use of gene fusions to
protein A and protein G in immunology and biotechnology.
Pathology Biology (Paris), 45, 66–76.
14. Kronvall, G., & Jonsson, K. (1999). Receptins: A novel term for
an expanding spectrum of natural and engineered microbial
proteins with binding properties for mammalian proteins. Journal
of Molecular Recognition, 12, 38–44.
15. Nagaoka, M., & Akaike, T. (2003). Single amino acid substitu-
tion in the mouse IgG1 Fc region induces drastic enhancement of
the afﬁnity to protein A. Protein Engineering, 16, 243–245.
16. Huse, K., Bohme, H. J., & Scholz, G. H. (2002). Puriﬁcation of
antibodies by afﬁnity chromatography. Journal of Biochemical
and Biophysical Methods, 51, 217–231.
17. Darby, C. R., Hamano, K., & Wood, K. J. (1993). Puriﬁcation of
monoclonal antibodies from tissue culture medium depleted of
IgG. Journal of Immunology Methods, 159, 125–129.
18. Andersen, D. C., Koch, C., Jensen, C. H., Skjødt, K., Brandt, J., &
Teisner, B. (2004). High prevalence of human anti-bovine IgG
antibodies as the major cause of false positive reactions in two-
site immunoassays based on monoclonal antibodies. Journal of
Immunoassay and Immunochemistry, 25, 17–30.
19. Zahnd, C., Amstutz, P., & Pluckthun, A. (2007). Ribosome dis-
play: Selecting and evolving proteins in vitro that speciﬁcally
bind to a target. Nature Methods, 4, 269–279.
20. Nord, O., Uhlen, M., & Nygren, P. A. (2003). Microbead display
of proteins by cell-free expression of anchored DNA. Journal of
Biotechnology, 106, 1–13.
21. Ohashi, H., Shimizu, Y., Ying, B., & Ueda, T. (2007). Efﬁcient
protein selection based on ribosome display system with puriﬁed
components. Biochemical and Biophysical Research Communi-
cations, 352, 270–276.
22. Nilsson, J., Larsson, M., Stahl, S., Nygren, P. A., & Uhlen, M.
(1996). Multiple afﬁnity domains for the detection, puriﬁcation
and immobilization of recombinant proteins. Journal of Molec-
ular Recognition, 9, 585–594.
23. Larsson, M., Graslund, S., Yuan, L., Brundell, E., Uhlen, M.,
Hoog, C., et al. (2000). High-throughput protein expression of
cDNA products as a tool in functional genomics. Journal of
Biotechnology, 80, 143–157.
24. Nossal, N. G., & Heppel, L. A. (1966). The release of enzymes by
osmotic shock from Escherichia coli in exponential phase.
Journal of Biological Chemistry, 241, 3055–3062.
25. Myszka, D. G. (1999). Improving biosensor analysis. Journal of
Molecular Recognition, 12, 279–284.
26. Rockberg, J., Lofblom, J., Hjelm, B., Uhlen, M., & Stahl, S.
(2008). Epitope mapping of antibodies using bacterial surface
display. Nature Methods, 5, 1039–1045.
27. Evans, M. S., Ugrinov, K. G., Frese, M. A., & Clark, P. L. (2005).
Homogeneous stalled ribosome nascent chain complexes pro-
duced in vivo or in vitro. Nature Methods, 2, 757–762.
28. Schafﬁtzel, C., & Ban, N. (2007). Generation of ribosome nascent
chain complexes for structural and functional studies. Journal of
Structural Biology, 158, 463–471.
29. Matsuura, T., Yanagida, H., Ushioda, J., Urabe, I., & Yomo, T.
(2007). Nascent chain, mRNA, and ribosome complexes gener-
ated by a pure translation system. Biochemical and Biophysical
Research Communications, 352, 372–377.
30. Contreras-Martinez, L. M., & DeLisa, M. P. (2007). Intracellular
ribosome display via SecM translation arrest as a selection for
antibodies with enhanced cytosolic stability. Journal of Molecu-
lar Biology, 372, 513–524.
31. Gunneriusson, E., Nord, K., Uhlen, M., & Nygren, P. (1999).
Afﬁnity maturation of a Taq DNA polymerase speciﬁc afﬁbody
by helix shufﬂing. Protein Engineering, 12, 873–878.
32. Derrick, J. P., & Wigley, D. B. (1992). Crystal structure of
a streptococcal protein G domain bound to an Fab fragment.
Nature, 359, 752–754.
33. Sauer-Eriksson, A. E., Kleywegt, G. J., Uhlen, M., & Jones, T. A.
(1995). Crystal structure of the C2 fragment of streptococcal pro-
tein G in complex with the Fc domain of human IgG. Structure, 3,
265–278.
34. Derrick, J. P., & Wigley, D. B. (1994). The third IgG-binding
domain from streptococcal protein G An analysis by X-ray
crystallography of the structure alone and in a complex with Fab.
Journal of Molecular Biology, 243, 906–918.
35. Sheriff, S., Jeffrey, P. D., & Bajorath, J. (1996). Comparison of
CH1 domains in different classes of murine antibodies. Journal of
Molecular Biology, 263, 385–389.
36. Boisbouvier, J., Blackledge, M., Sollier, A., & Marion, D. (2000).
Simultaneous determination of disulphide bridge topology and
three-dimensional structure using ambiguous intersulphur dis-
tance restraints: Possibilities and limitations. Journal of Biomo-
lecular NMR, 16, 197–208.
37. Mattheakis, L. (1994). An in vitro polysome display system for
identifying ligands from very large peptide libraries. Proceedings
of the National Academy of Sciences, 91, 9022–9026.
276 Mol Biotechnol (2011) 48:263–276
123